Compare Carlyle Group Inc (CG) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Cronos Group Inc — how do they compare? Carlyle Group Inc trades at $48.27 (market cap $17.23B), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Carlyle Group Inc is far larger — about 15.1× Cronos Group Inc's market cap, and Carlyle Group Inc pays a 2.9% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CG | CRON | |
|---|---|---|
Market Cap | $17.23B | $1.14B |
Sector | Financials | Health |
52-Week High | $69.35 | $3.27 |
52-Week Low | $40.52 | $2.30 |
Dividend Yield | 2.9% | — |
Enterprise Value | — | $341.13M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
